Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
Aquestive Therapeutics will present new clinical data on its Anaphylm (dibutepinephrine) sublingual film at the 2026 AAAAI Annual Meeting. The data highlight Anaphylm's ability to achieve clinically relevant epinephrine plasma concentrations without causing a diastolic blood pressure dip, a significant improvement for anaphylaxis treatment. The company believes Anaphylm offers a convenient, easy-to-carry alternative to injectable epinephrine, potentially transforming anaphylaxis management.
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm. The FDA's concerns about Anaphylm, an experimental sublingual film for severe allergic reactions, could prevent approval before the January 31, 2026, PDUFA action date. Investors who suffered significant losses in Aquestive Therapeutics stock or options are encouraged to contact the law firm to discuss their legal rights.
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer
Aquestive Therapeutics has appointed Dr. Matthew Greenhawt, an expert in allergy and immunology, as its new Chief Medical Officer. This appointment comes as the company prepares to resubmit its New Drug Application for Anaphylm, a needle-free treatment for severe allergic reactions, to the FDA. The company is working to address issues raised in a recent Complete Response Letter from the FDA regarding the application.
Anaphylaxis researcher joins Aquestive to tackle epinephrine access barriers
Aquestive Therapeutics has appointed Dr. Matthew Greenhawt, an internationally recognized allergist and researcher, as its new Chief Medical Officer. This strategic hire aims to support the planned resubmission of the Anaphylm (dibutepinephrine) NDA and advance the company’s clinical pipeline. Dr. Greenhawt brings extensive expertise in food allergy, anaphylaxis, and patient advocacy, which will be crucial as Aquestive addresses real-world barriers to epinephrine use.
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential legal claims on behalf of investors who suffered significant losses in Aquestive Therapeutics (NASDAQ: AQST) stock or options. This investigation follows a approximately 40% intraday drop in Aquestive shares after the company disclosed that the U.S. FDA identified deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability. Investors affected are encouraged to contact Faruqi & Faruqi for a discussion of their legal options.
Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug
Aquestive Therapeutics (NASDAQ: AQST) experienced a significant stock drop of 40% after the FDA identified deficiencies in its New Drug Application (NDA) for Anaphylm, a drug for severe allergic reactions. This setback casts doubt on the drug's approval path, which could negatively impact the company's future revenue and growth. The FDA's decision raises concerns about Anaphylm's safety, efficacy, or manufacturing ahead of its PDUFA action date.
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential securities claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged due to an FDA disclosure of deficiencies in its New Drug Application for Anaphylm. The FDA's findings raise concerns about the drug's approvability ahead of its PDUFA action date. Investors who suffered significant losses in Aquestive Therapeutics stock are encouraged to contact the law firm to discuss their legal options.
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after its stock plunged following the FDA's identification of deficiencies in the New Drug Application for its experimental drug Anaphylm. These deficiencies reportedly prevent discussions of labeling and post-marketing requirements, raising concerns about the drug's approvability before its PDUFA action date. Investors who suffered significant losses in Aquestive Therapeutics stock or options are encouraged to contact the law firm to discuss their legal options.
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (NASDAQ:AQST) shareholders. This investigation follows a significant drop in Aquestive's stock price by over 37% after the FDA identified deficiencies in the Company's NDA for Anaphylm, precluding immediate discussions on labeling and post-marketing commitments. The law firm is encouraging affected shareholders to contact them to learn more about the investigation.
Federated Hermes Inc. Takes $4.38 Million Position in Aquestive Therapeutics, Inc. $AQST
Federated Hermes Inc. has acquired a new stake of 783,778 shares in Aquestive Therapeutics (NASDAQ: AQST), valued at $4.38 million, representing 0.79% ownership. Institutional investors collectively hold about 32.45% of AQST stock. Despite mixed analyst sentiment, with some upgrading and some downgrading, the average rating remains "Buy" with a consensus price target of $8.50, even though the company recently missed quarterly EPS estimates and has a negative full-year EPS forecast.
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the FDA identified deficiencies in its New Drug Application for Anaphylm, an experimental sublingual film. This disclosure caused Aquestive's stock to plunge significantly. Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal options.
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA for its Anaphylm™ New Drug Application, citing deficiencies in human factors validation related to packaging and administration. The company believes it can resolve these issues, primarily concerning pouch opening and film placement, and plans to resubmit as early as Q3 2026 after conducting new human factors and parallel pharmacokinetic studies. Aquestive remains confident in Anaphylm's potential as a non-invasive epinephrine treatment and is also advancing global regulatory submissions in Canada and Europe.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
Aquestive Therapeutics (NASDAQ:AQST) shares have recently fallen by 36%, yet its price-to-sales (P/S) ratio of 11.2x remains elevated compared to the average pharmaceutical industry P/S of 4.5x. This high valuation persists despite a revenue decline of 26% last year and 9.7% over the past three years. Analysts, however, project a 31% annual revenue growth for the company over the next three years, aligning with industry forecasts, which raises questions about the justification for its current high P/S ratio.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
Aquestive Therapeutics (NASDAQ:AQST) experienced a 36% share price drop recently, despite a 29% gain over the last year. The company's price-to-sales (P/S) ratio of 11.2x is notably high compared to the pharmaceutical industry average, signaling potential overvaluation given its declining revenue. While analysts forecast a 31% annual growth for Aquestive Therapeutics over the next three years, aligning with industry trends, its current high P/S ratio suggests investors might be overly optimistic, potentially leading to disappointment if the P/S ratio adjusts to reflect its growth outlook.
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026
Analysts have significantly lowered their revenue estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST) for 2026, forecasting US$48m instead of the previous US$64m, while maintaining loss per share estimates at US$0.58. Despite the downgrade, the share price has risen by 18% recently, and analysts have increased their price target to US$9.22 per share. The company's revenue growth is expected to accelerate, matching the industry average, but the substantial downgrade suggests investors should be cautious.
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026
Analysts have significantly cut their 2026 revenue estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST), reducing them from US$64m to US$48m, while keeping loss per share forecasts steady at US$0.58. Despite the bearish outlook for revenues, the company's share price has seen an 18% increase in the past week, and analysts have also raised their price target to US$9.22. The article suggests investors should be wary due to the drastic downgrade, compounded by significant stock dilution in the past year.
What Does the Market Think About Aquestive Therapeutics Inc?
Aquestive Therapeutics Inc.'s (NYSE: AQST) short interest as a percent of float has increased by 10.15% since its last report, with 24.14 million shares sold short, representing 22.69% of tradable shares. This indicates a more bearish sentiment among investors compared to its peers, whose average short interest is 12.23%. Based on its trading volume, it would take traders 10.35 days to cover their short positions.
Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm
Aquestive Therapeutics (AQST) valuation is under scrutiny after the FDA issued a Complete Response Letter for its Anaphylm epinephrine sublingual film, sparking significant stock price fluctuations. While a popular narrative suggests the company is 60.2% undervalued with a fair value of $10.30, based on Anaphylm's potential, its current P/S ratio of 11.5x far exceeds the industry average of 4.3x, hinting at a valuation risk. The article encourages investors to analyze the underlying assumptions and risks, including reliance on Anaphylm's approval and potential shareholder dilution.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update
Aquestive Therapeutics (NASDAQ:AQST) experienced a significant 15.9% decline in short interest in January, totaling 20,296,603 shares, which represents about 18.1% of its shares sold short and a days-to-cover ratio of 2.3 days. The company's stock is trading near $2.95, below its 50- and 200-day moving averages, with a market cap of approximately $360 million. Analysts maintain a consensus "Buy" rating with an $8.83 target price, despite mixed opinions and a recent EPS loss of $0.14.
Regulatory clarity lifts Aquestive despite CRL for Anaphylm
Aquestive Therapeutics Inc.'s share price rose 39% despite receiving a Complete Response Letter (CRL) from the U.S. FDA for its drug Anaphylm (dibutepinephrine). The market reacted positively to regulatory clarity, even though the CRL delays the commercial entry of this potential oral alternative to Epipen. This situation is unusual, as CRLs typically cause a stock decrease.
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. This follows a more than 37% stock drop after the FDA identified deficiencies in Aquestive's NDA for Anaphylm, preventing discussions on labeling and post-marketing commitments. The firm is encouraging shareholders who suffered losses to participate in the investigation.
US FDA declines to approve Aquestive's oral drug for allergic reactions
The U.S. Food and Drug Administration (FDA) has declined to approve Aquestive Therapeutics' oral drug, Anaphylm, for severe allergic reactions, citing concerns about product packaging and ease of use in an emergency. This decision creates an opportunity for ARS Pharma's nasal treatment, Neffy, to solidify its market position as Aquestive aims to resubmit its application as early as Q3 2026. Aquestive shares were halted in premarket trading following the announcement.
Allergy rescue film setback: FDA flags Anaphylm packaging, eyed for Q3 2026
Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA for its Anaphylm (dibutepinephrine) Sublingual Film, citing deficiencies related to human factors in packaging and administration, and requesting a supportive pharmacokinetic study. The company plans to address these issues by modifying packaging and instructions, conducting new studies, and aims for a resubmission in Q3 2026, while remaining confident in the drug's safety and effectiveness. Aquestive also intends to pursue international regulatory approvals in Europe and Canada in H2 2026, and believes it has sufficient funding for these activities.
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Aquestive Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its Anaphylm™ New Drug Application, citing deficiencies related to packaging, administration, and human factors study. The company believes these issues are rapidly resolvable and plans to resubmit as early as Q3 2026, with no concerns raised regarding the drug's efficacy, safety, or CMC. Aquestive also plans global submissions in Canada and the EU by the end of 2026.
Aquestive Therapeutics Stock Surges 43% Over Complete Response Letter From FDA For Anaphylm NDA
Aquestive Therapeutics (AQST) stock surged 43% following a Complete Response Letter from the FDA for its Anaphylm Sublingual Film NDA. The company plans to request a Type A meeting with the FDA and estimates resubmission in the third quarter of 2026, seeking rapid review. This news caused AQST shares to open at $3.79 and climb to $4.39.
Aquestive shares slide after FDA flags issues in Anaphylm filing
Aquestive Therapeutics (AQST) shares fell sharply after the FDA identified deficiencies in its Anaphylm new drug application for allergic reactions, preventing a discussion of the drug's efficacy and safety. The company plans to address these issues promptly, emphasizing the FDA's notice does not question the drug's clinical data or manufacturing. Despite the setback, Aquestive remains committed to securing approval for its epinephrine-delivery film.
Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Aquestive Therapeutics (NASDAQ:AQST) from "hold" to a "sell" rating, with Weiss Ratings also maintaining a "sell" view. Despite this, the company holds an average "Buy" rating and an average price target of $8.83 from other analysts. Aquestive Therapeutics is currently trading around $2.95, down 6.6%, with a market cap of approximately $360 million, after slightly missing recent quarterly revenue and EPS estimates.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40%. This decline followed the FDA's identification of deficiencies in Aquestive's New Drug Application for Anaphylm, raising concerns about its approvability. The law firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors of Aquestive Therapeutics (NASDAQ: AQST) after the company's stock plunged approximately 40%. This decline followed the FDA identifying deficiencies in Aquestive's New Drug Application for Anaphylm, its experimental treatment for severe allergic reactions, which raises concerns about its approvability. Investors who suffered significant losses are encouraged to contact Faruqi & Faruqi to discuss their legal options.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock price fell significantly following an FDA notification about deficiencies in its NDA for Anaphylm. The firm advises investors to contact them regarding potential securities fraud or unlawful business practices by Aquestive's officers and/or directors. This investigation follows a 37.04% drop in Aquestive's stock price on January 9, 2026, after the FDA cited unspecified deficiencies that precluded labeling and post-marketing discussions for Anaphylm.
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40% when the FDA identified deficiencies in its New Drug Application (NDA) for Anaphylm. These deficiencies prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability before the January 31, 2026, PDUFA action date. Investors who suffered significant losses are encouraged to contact the firm.
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40% following an FDA announcement. The FDA identified deficiencies in Aquestive's New Drug Application for Anaphylm, preventing discussions of labeling and post-marketing requirements. Investors who suffered significant losses are encouraged to contact Faruqi & Faruqi to discuss their legal options.
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's shares plunged following an FDA disclosure of deficiencies in its New Drug Application for Anaphylm. These deficiencies reportedly prevent discussions of labeling and post-marketing requirements, raising concerns about the drug's approvability before the January 31, 2026, PDUFA action date. The law firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts
Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus "Buy" rating from analysts, with an average 12-month price target of $8.83 based on ten analyst ratings. Recent analyst actions include Piper Sandler raising its price target to $8 and JMP Securities to $12, while Zacks upgraded the stock to "strong-buy." The company's stock currently trades around $3.24, with a market capitalization of $395.28 million and a negative P/E ratio, after reporting a quarterly EPS of ($0.14), slightly missing analyst estimates.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating Aquestive Therapeutics, Inc. (AQST) regarding potential securities fraud or unlawful business practices. This investigation follows a significant 37.04% drop in Aquestive's stock price on January 9, 2026, after the FDA identified deficiencies in its Anaphylm NDA. Investors are encouraged to contact Pomerantz LLP to inquire about joining a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the FDA identified deficiencies in its NDA for Anaphylm, which led to a significant drop in the company's stock price. Investors are advised to contact the law firm regarding potential securities fraud or unlawful business practices.
Jim Cramer on Aquestive Therapeutics: “I’m Not Sure If They Deserve the Benefit of the Doubt”
Jim Cramer discussed Aquestive Therapeutics (NASDAQ: AQST) after its stock plunged following an FDA "slap down" regarding its drug Anaphylm. Despite the company's confidence and past secondary offering, Cramer expressed reduced confidence due to the ambiguous nature of the FDA's decision and the risks associated with speculative biotech stocks, advising against new purchases while acknowledging potential for existing holders. He highlighted the broader lesson about understanding the risks of speculative investments versus more stable large-cap pharma companies.
AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Aquestive Therapeutics, Inc. on behalf of its stockholders. This investigation follows Aquestive's disclosure that the FDA identified deficiencies in its New Drug Application for Anaphylm™, causing a drop in the company's stock price. The law firm encourages affected investors to contact them to discuss their legal options.
AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) after the company disclosed that the FDA identified deficiencies in its New Drug Application for Anaphylm™. This news led to a drop in Aquestive's stock price. The firm is encouraging investors who suffered losses to contact them to discuss potential claims regarding federal securities laws violations and unlawful business practices.
Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge Due to FDA Concerns
Faruqi & Faruqi is investigating Aquestive Therapeutics following a significant 40% intraday stock drop. This plunge occurred after the FDA identified deficiencies in Aquestive's New Drug Application for Anaphylm, raising concerns about its approval despite some analysts maintaining positive price targets prior to this recent news. The law firm is encouraging investors who have incurred substantial losses to contact them regarding potential claims.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics (NASDAQ: AQST) after the company's shares plunged approximately 40%. This decline occurred following the FDA's identification of deficiencies in Aquestive's New Drug Application for Anaphylm, an experimental sublingual film for severe allergic reactions, raising concerns about its approvability. The law firm is encouraging investors who suffered significant losses to contact them to discuss legal options.
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Aquestive Therapeutics, Inc. (AQST) for potential securities law violations after the company announced on January 9, 2026, that the FDA identified deficiencies in its NDA for Anaphylm, precluding labeling discussions. This news led to a significant 37.04% decline in Aquestive's stock price. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding the investigation.
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Aquestive Therapeutics, Inc. (AQST) for potential securities law violations after the company announced that the FDA identified deficiencies in its New Drug Application (NDA) for Anaphylm. This news led to a significant 37.04% drop in Aquestive's stock price on January 9, 2026. The law firm is seeking information from investors who have suffered losses and may have claims.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant 37.04% drop in Aquestive's stock price on January 9, 2026, after the FDA identified deficiencies in the company's NDA for Anaphylm, precluding labeling discussions. Investors are encouraged to contact the law firm to learn about joining a potential class action.
A Look At Aquestive Therapeutics (AQST) Valuation After Anaphylm Regulatory Update And FDA Feedback
Aquestive Therapeutics (AQST) has seen a sharp decline in its share price following a regulatory update on its Anaphylm sublingual epinephrine film, despite a significant 3-year shareholder return. The article discusses AQST's valuation, noting its "62% Undervalued" status based on a narrative fair value of US$10.30, heavily reliant on Anaphylm's potential success. However, it also presents a contrasting view, highlighting the company's high Price-to-Sales ratio compared to industry peers, suggesting the market might already be premium-pricing future growth that is not yet profitable.
Commonwealth Equity Services LLC Takes $5.92 Million Position in Aquestive Therapeutics, Inc. $AQST
Commonwealth Equity Services LLC has acquired a new position of 1,058,725 shares in Aquestive Therapeutics (NASDAQ: AQST), valued at approximately $5.92 million. Despite recent analyst upgrades and a "Buy" consensus rating with an average price target of $8.83, the company reported an EPS miss and analysts project continued losses for the current year. The stock opened at $3.52 and has a 52-week trading range of $2.12 to $7.55.
Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST)
Levi & Korsinsky has initiated an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential federal securities law violations. This comes after Aquestive announced on January 9, 2026, that the FDA identified deficiencies in its NDA for Anaphylm, leading to a significant 35.1% drop in the company's stock price. The firm is inviting investors who suffered losses to explore legal recovery options.
Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now
Aquestive Therapeutics (AQST) shows potential for a trend reversal despite a recent 45.2% stock drop, indicated by a hammer chart pattern formation. This technical signal, combined with positive earnings estimate revisions and a Zacks Rank #2 (Buy), suggests that the stock could be a "buy the bottom" opportunity. Analysts are in strong agreement about the company's improved earnings prospects, further supporting a potential turnaround.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. after the company's stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application for Anaphylm. These deficiencies currently prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026, PDUFA action date. Investors who suffered significant losses are encouraged to contact Faruqi & Faruqi for legal consultation.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of investors following a significant drop in stock price. This investigation stems from the FDA identifying deficiencies in Aquestive's NDA for Anaphylm, which led to a 37.04% stock decline on January 9, 2026. The law firm is exploring potential securities fraud or unlawful business practices by the company's officers and/or directors.
